KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $1.2 billion.

  • Teva Pharmaceutical Industries' Cash from Operations rose 10139.13% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.6 billion, marking a year-over-year increase of 3223.74%. This contributed to the annual value of $1.6 billion for FY2025, which is 3223.74% up from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Cash from Operations stood at $1.2 billion, which was up 10139.13% from $369.0 million recorded in Q3 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Cash from Operations peaked at $1.2 billion during Q4 2023, and registered a low of -$405.0 million during Q1 2021.
  • For the 5-year period, Teva Pharmaceutical Industries' Cash from Operations averaged around $332.6 million, with its median value being $275.5 million (2023).
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Cash from Operations tumbled by 23278.69% in 2021, and later surged by 1376000.0% in 2024.
  • Over the past 5 years, Teva Pharmaceutical Industries' Cash from Operations (Quarter) stood at $456.0 million in 2021, then soared by 113.38% to $973.0 million in 2022, then increased by 21.69% to $1.2 billion in 2023, then crashed by 51.44% to $575.0 million in 2024, then soared by 101.39% to $1.2 billion in 2025.
  • Its Cash from Operations was $1.2 billion in Q4 2025, compared to $369.0 million in Q3 2025 and $227.0 million in Q2 2025.